Kornimate/medical-research-clean huggingface dataset:
in-vivo validation of novel diagnostic devices versus visual icdas-ii criteria in detection of early occlusal caries

Conditions: Dental Caries (Diagnosis)

Summary: the diagnosis of non-cavitated occlusal caries is considered problematic and still a challenge for dental professionals. it affects 60-90% of schoolchildren and adults.clinically, caries commonly is performed by methods of visual examination and subjective assessments of, translucency, color and dental hardness, as well as by means of radiographic imaging. these methods, however, show low sensitivity for occlusal caries detection.some of these methods are light based fluorescence devices taking the advantages of the fluorescence properties of the hard tissues of the tooth as there is a difference in fluorescence observed in sound and demineralized dental tissues.other methods based on electrical impedance has been used. these devices aimed to employ the ac impedance spectroscopy technique (acist) in order to record variations in mineral density throughout the tooth, not just the surface, acist sends a low amplitude microamp current from the sensor tip contact through the pulp, dentin, and enamel.hence, a diagnostic accuracy study control trial is to be held to evaluate the clinical performance of quantitative light fluorescence based device (vistacam proof) and impedance spectroscopy based device (cariescanpro) in comparison with the visual examination and digital radiography in detection of initial pits and fissures caries.


Eligibility criteria:
inclusion criteria: * patients aged from 21 to 50 years. * patient at least has one posterior pits and fissure occlusal caries. * no gender restriction * co-operative patients who signed the informed consent. * good general health * acceptable oral health exclusion criteria: * pregnancy. * disabilities. * systemic disease or severe medical complications. * allergic history concerning methacrylate. * rampant caries. * heavy smoking. * xerostomia. * lack of compliance. * evidence of severe bruxism, clenching, or temporomandibular joint disorders
effect of diaphragmatic release on upper crossed syndrome

Conditions: Neck Muscle Issue; Kyphosis

Summary: the study aims to investigate the effectiveness of diaphragmatic release on upper crossed syndrome

poor posture typically causes upper cross syndrome, resulting in neck pain. neck pain is the most common reason for patients to visit healthcare professionals. this syndrome can cause dysfunctional tone in posture and muscular disparity of the head, neck, and shoulder region . evidence suggests that 6-48% of the upper crossed syndrome population complain of pain in the shoulder girdle and cervicothoracic region. many disorders are linked with the upper crossed syndrome, including migraine headaches; chronic headaches; subacromial impingement; biceps tendinitis; thoracic outlet syndrome; degeneration of the cervical spine; and joint dysfunction at the c1-c2 segment, c4-c5 segment, cervicothoracic joint, and t4-t5 segment. upon the available research studies, there is no study conducted to investigate the effect of diaphragmatic release on upper crossed syndrome patients.

Eligibility criteria:
inclusion criteria: * age ranged from 17 to 22 years . * body mass index from 20 to 25 kg/m². * all participants have an intensity of neck pain on vas (4-8) (moderate cases). * the subjects were chosen from both sexes. * all participants have kyphosis angle ≥42° * all participants have mechanical neck pain and fhp (craniovertebral angle cva \< 49). exclusion criteria: * malignancy * fractures of the cervical spine * cervical radiculopathy or myelopathy * vascular syndromes such as vertebrobasilar insufficiency * rheumatoid arthritis * neck or upper back surgery * taking anticoagulants * local infection * whiplash injury
to evaluate kc1036 in the patients with advanced digestive system tumors

Conditions: Digestive System Tumors

Summary: the purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of kc1036 in participants with advanced recurrent or metastatic digestive system tumors.

this is an open label, non-randomized，phase 1b/2 study to explore the preliminary antitumor activity of kc1036 in patients with advanced recurrent or metastatic digestive system tumors under bid or qd regimen. the study will consist of two parts: part 1: qd regimen to evaluate the efficacy and safety of kc1036 in the treatment of advanced recurrent, unresectable and / or metastatic digestive system tumors under 60mg qd regimen. part 2: bid regimen dose-escalation part : to explore the safety of kc1036 under 20mg bid, 30mg bid and 40mg bid in patients with advanced recurrent or metastatic digestive system tumors. dose-expansion part : according to the results of dose-escalation, an appropriate bid regimen was selected for dose-expansion to evaluate the effectiveness and safety of kc1036 in patients with advanced recurrent, unresectable and / or metastatic digestive system tumors.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed malignant digestive system tumors; * patients with advanced recurrent, unresectable and / or metastatic digestive system tumors who have failed standard or conventional treatment:( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment); * eastern cooperative oncology group performance status score of 0 or 1; * life expectancy \> 12 weeks; * bmi≥18.0; * has adequate hematologic, renal, and hepatic function; * patients should participate in the study voluntarily and sign informed consent. exclusion criteria: * any patient who is known to have central nervous system (cns) metastasis with clinical symptoms; * other kinds of malignancies; * gastrointestinal abnormalitiest; * cardiovascular and cerebrovascular diseases; * previous treatment with small molecule vascular targeting inhibitor； * prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks before enrollment; * involved in other clinical trials within 4 weeks before enrollment; * major surgical procedure, open biopsy, or significant traumatic injury 4 weeks before enrollment; * uncontrolled massive ascites,pleural/pericardial effusion; * uncontrolled ongoing or active bacterial, viral or fungal infectious; fever of unknown cause (\> 38.5 ℃) occurred within 2 weeks before enrollment; * known history of human immunodeficiency virus (hiv) infection or current chronic or active hepatitis b or c infection ; * pregnant or lactating women or those who do not take contraceptives, including men; * any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings; * inability to comply with protocol required procedures.
assessment of the impact of increased production of reactive oxygen species produced during repeated sessions of hyperbaric oxygen therapy in patients undergoing radiotherapy for neoplasia, on the occurrence of dna damage

Conditions: Hyperbaric Oxygen; Genotoxicity; Malignancy

Summary: hyperbaric oxygen therapy (hbot) is a treatment involving the administration of oxygen at pressures higher than atmospheric pressure, with numerous potential indications such as radiation-induced tissue damage, chronic wounds, and more. hbot significantly increases the amount of dissolved oxygen in tissues, thereby promoting wound healing. however, this "hyperoxygenation" may also exert toxic effects, particularly through the production of reactive oxygen species (ros), which can induce dna damage and potentially promote mutagenesis, thereby increasing long-term neoplastic risk. a single hbot session is associated with a significant increase in ros production, which may persist for up to 48 hours post-exposure, and is also linked to dna damage. dna repair is typically a rapid process, with the activation of protective mechanisms. the effects of repeated hbot sessions remain a matter of debate. reported outcomes range from attenuation of genotoxicity, to exacerbation of dna damage, or no effect at all (8). in patients with cancer or comorbidities associated with impaired dna repair capacity, repeated hbot could be more detrimental, potentially increasing genotoxic effects and cancer risk. this increased oxygen susceptibility in cancer patients has already been observed in normobaric conditions during abdominal surgery, where hyperoxygenation strategies were associated with increased mortality in this subgroup. a potential pro-carcinogenic effect of hbot in cancer patients has also been suggested in some case series, though not confirmed by larger studies. current literature on hbot safety remains generally reassuring; however, the possibility of dna damage and its potential long-term genotoxic consequences cannot be entirely excluded. this question is of particular importance given that many primary indications for hbot involve patients with a history of malignancy or active cancer


Eligibility criteria:
inclusion criteria: * adults (≥18 years old) * having signed an informed consent form * affiliated with or beneficiary of a national health insurance system * admitted to the hyperbaric medicine department for hbot treatment * either for a complication related to prior radiotherapy (administered for an underlying neoplastic disease), such as: radiation cystitis radiation proctitis / enteritis radiation dermatitis mandibular osteoradionecrosis or for another indication, without any underlying neoplastic disease exclusion criteria: * patients with a contraindication to hyperbaric oxygen therapy (hbot) * pregnant, breastfeeding, or postpartum women * patients deprived of liberty by judicial or administrative decision * patients undergoing involuntary psychiatric treatment * patients under legal guardianship or protective custody
the aim is to estimate the total amount of insulin-producing cells in the pancreas by mri.

Conditions: Diabetes Mellitus

Summary: assess pancreatic beta cell function using mr imaging.

the study was terminated on july 31st, 2007. the study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. there were no safety concerns.

Eligibility criteria:
inclusion criteria: * normal volunteers * t1dm and t2dm subjects exclusion criteria: * concomitant severe conditions
visual feedback goggle for positional vertigo treatment

Conditions: Positional Vertigo; Vertigo

Summary: benign paroxysmal positional vertigo (bppv) is one of the most common causes of vertigo and the most common vestibular disorder of the inner ear. bppv is the result of small free-floating particles (canaliths) in the posterior semicircular canals where they aggravate the sensory apparatus and induce sudden and severe attacks of vertigo when the head is turned into certain positions. the treatment of bppv was revolutionized by the introduction of the epley maneuver, a sequence of head movements that use gravity to reposition the canaliths within the inner ear. the epley maneuver provides prompt relief from vertigo in approximately 80% of patients. the innovation, the vertigone goggle, provides both physician and patient with visual feedback to guide them through an accurate epley maneuver. this changes the current treatment paradigm for bppv, greatly increasing the availability of the maneuver to non-specialist physicians, nurse practitioners, physician's assistants and physical therapists. the device is designed so that the patient with recurrent vertigo can use the goggle to treat bppv at home. the goggle is currently a pre-market prototype. the hypothesis for the study is that accuracy in the performance of the epley maneuver correlates with improved clinical resolution of vertigo in bppv patients. if the hypothesis is true, then there is a clear case for the utility of the visual feedback provided by the vertigone goggle in performing the maneuver.


Eligibility criteria:
inclusion criteria: * age: 30-80 * old patients (more than one year since first symptom)or new patients(more than 3 months duration of symptoms) diagnosed by physicians with benign paroxysmal positional vertigo (bppv) * must have good neck flexibility to perform the movements of the epley maneuver * subject is willing and able to provide written informed consent * subject is willing to remain in the clinic for the treatment and follow-up visits exclusion criteria: * age \ 80 * can not perform the movements of the epley maneuver * no informed consent form * not willing to remain in the clinic for the treatment and follow-up visits

Keywords: vertigo benign paroxysmal positional vertigo bppv positional vertigo
3d dl ozteo in the detection of osseous changes in patients with inflammatory arthritis

Conditions: Inflammatory Arthritis

Summary: this project intends to explore and validate the utility of new mri pulse sequence, 3d dl ozteo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. the detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. currently, this is most often assessed with radiography and conventional mri.

this project intends to explore and validate the utility of new mri pulse sequence, 3d dl ozteo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis.

Eligibility criteria:
inclusion criteria: * adult patients ≥18 years of age * hand radiographs performed within the past 3-6 months with imaging results available for analysis * hand radiographs confirm the presence of bony erosions * scheduled for a hand mri as part of their routine clinical care at mayo clinic rochester exclusion criteria: - less than18 years of age
an efficacy study of secukinumab in plaque psoriasis patients with subclinical psoriatic arthritis as measured by musculoskeletal ultrasound

Conditions: Psoriasis

Summary: given the role of il-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking il-17 would be a logical option for the treatment of subclinical enthesitis in psoriasis patients. this study will be the first randomized trial of a biologic therapy versus placebo in participants with plaque psoriasis and subclinical psoriatic arthritis, using musculoskeletal ultrasound.

the primary objective of this study is to estimate the difference in effect between secukinumab 300 mg s.c. and placebo, based on change from baseline to week 16 in the omeract ultrasound enthesitis score.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic plaque-type psoriasis confirmed through physical examination by a dermatologist, with at least six months of clinical history prior to the baseline visit * moderate to severe plaque psoriasis at baseline as defined as: * ≥ 10 % body surface area (bsa) involvement, or * ≥ 3% to \<10% body surface area with involvement of special regions (nails, scalp, or intertriginous skin), or with a history of psoriatic arthritis in a parent candidate for systemic therapy, defined as having psoriasis inadequately controlled by current topical and/or systemic treatment(s) (including topical corticosteroids), phototherapy, or previous systemic therapies presence of sonographic enthesitis at screening, in at least one enthesis, defined by the presence of at least abnormal thickening and hypoechogenicity of the tendon insertion, with or without presence of doppler signal (grade 0-3), or by the presence of grade ≥ 2 doppler signal, independent of gray scale abnormalities exclusion criteria: * diagnosis of psa as per caspar confirmed by a rheumatologist (including the presence of inflammatory pain in entheses or joints), and any other known rheumatological disease affecting the assessed joints * exposure to any il-17 or il-23(p19) inhibitor for the treatment of psoriasis (approved or investigational) within twelve months prior to screening, or exposure to any inhibitors of tnf-ɑ and il12/23 within six months prior to screening * previous exposure to non-biologic systemic therapy for psoriasis, including methotrexate, pde-4 inhibitors, or systemic corticosteroids within 12 weeks or 5 half-lives (whichever is longer) prior to screening * a degree of obesity that impedes proper ultrasound examination of entheses and joints * forms of diagnosed psoriasis other than chronic plaque psoriasis (e.g., erythrodermic, generalized or localized pustular psoriasis, or new onset guttate psoriasis) other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriasis subclinical enthesitis secukinumab subclinical psoriatic arthritis plaque psoriasis ain457
lung cancer screening with low-dose ct scan in women : implementation study

Conditions: Lung Cancer Screening

Summary: the purpose of this study is to determine whether reading of low-dose thoracic ct scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts. the study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.

lung cancer is the leading cause of cancer death, worldwide. several randomized studies have demonstrated that annual or biennial low-dose ct screening reduces lung cancer mortality. however, these studies involved expert chest radiologists, with double reading being performed in most studies. furthermore, none of the published studies have evaluated the role of artificial intelligence to serve as second of concurrent reader. women with at least 20 pack-year smoking history who quitted smoking less than 15 years ago will be enrolled to have baseline, 1-year and 2-year low-dose ct of the chest. the ct scans will be read on site by a general radiologist trained to lung cancer screening according to the european lung cancer screening certification program, first without then with the aid of an artificial algorithm trained to lung nodule detection (veye chest, aidence). all ct scans will also be read by 2 chest experts, who will resolve their disagreement by a consensus reading if necessary. patient management will rely on the double reading by expert. the criteria for positive screen result are as follows: solid nodule \> 500 mm3 (10 mm) or growing (30% volume increase), part-solid nodule with \> 8 mm solid component or new or growing, pure ground glass nodule developing a solid portion.

Eligibility criteria:
inclusion criteria: * women aged from 50 to 74 years * who had smoked at least 20 pack years and quit less than 15 years ago * had given their consent and accepted the need for a 2-year follow-up * affiliated to the social security system exclusion criteria * presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever) * evolving cancer * history of lung cancer * a 2-year follow-up not possible * chest ct scan performed within 2 years prior to inclusion

Keywords: lung neoplasms multidetector computed tomography early detection of cancer artificial intelligence lung cancer screening
effects of ras in stroke

Conditions: Stroke

Summary: the goal of this study is to to examine whether rhythmic auditory stimulation improved movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients. the main questions it aims to answer are: * does rhythmic auditory stimulation improve movement speed in stroke patients? * does rhythmic auditory stimulation improve movement function of executing activities of daily living in stroke patients? * does rhythmic auditory stimulation improve movement recovery of the affected upper limb in stroke patients? * does rhythmic auditory stimulation improve quality of life in stroke patients? researchers will compare movement training with the aid of rhythmic auditory stimulation to movement training without the aid of rhythmic auditory stimulation to see if rhythmic auditory stimulation works to improve movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients. participants will: * undergo movement tests and fill out questionnaires before and after the movement training program * receive movement training for 40 minutes per session and three sessions per week for a total of 24 sessions


Eligibility criteria:
inclusion criteria: * (1) diagnosed with either ischaemic or hemorrhagic stroke, and a first-time occurrence; * (2) a unilateral stroke; * (3) the onset occurred six months or more prior to the experiment, indicating a chronic stage of stroke; * (4) the affected upper limb's proximal and distal joints are between brunnstrom stages four to six, ensuring that the affected limb can execute the upper-limb functional movement training of this study; * (5) the affected upper limb's modified ashworth scale score is ≤ 2, indicating no significant muscle stiffness (spasticity) in the affected limb; * (6) a montreal cognitive assessment score of ≥ 24, ensuring comprehension of the instructions given during this study; * and (7) when we clap hands next to the affected ear of the participant who closes eyes, the participant is able to indicate the sound's source either verbally or through gestures, indicating no complete hearing loss in the affected ear and the ability to receive rhythmic auditory stimulation. exclusion criteria: * (1) neurological diseases or medical conditions that affect upper-limb movements or hearing; * (2) being participating in other experimental studies related to drug treatment or upper-limb movement therapy.
dark halo and mnv: a study between icga and octa

Conditions: Macular Neovascularisation

Summary: the aim of study is to compare the evaluation of dark halo area of macular neovascularization (mnv) between indocyanine green angiography (icga) and optical coherence tomography angiography (octa) in order to identify octa as effective and useful biomarker in mnv

dark halo is defined as a dark perilesional of flow decrease due to an area of reduced choroidal flow adjacent to the macular neovascularization (mnv). the detection of mnv vascular details was only possible through invasive dye injection, such as fluorescein angiography (fa) or indocyanine green angiography (icga). optical coherence tomography angiography (octa) is a recent imaging technique that is able to detect the perfusion and non-perfusion areas carefully. the aim of study is to compare the evaluation of dark halo area of mnv between icga and octa

Eligibility criteria:
inclusion criteria: * age older than 55 years * diagnosis of macular neovascularization * absence of previous treatment with anti-vegf injections * absence of other retinal vascular diseases exclusion criteria: * age younger than 55 years * absence diagnosis of macular neovascularization * presence of previous treatment with anti-vegf injections * presence of other retinal vascular diseases